Maeva Dufies

2.4k total citations
46 papers, 1.5k citations indexed

About

Maeva Dufies is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Maeva Dufies has authored 46 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 18 papers in Oncology and 11 papers in Hematology. Recurrent topics in Maeva Dufies's work include Chronic Myeloid Leukemia Treatments (9 papers), Renal cell carcinoma treatment (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Maeva Dufies is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Renal cell carcinoma treatment (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Maeva Dufies collaborates with scholars based in France, Monaco and United States. Maeva Dufies's co-authors include Patrick Auberger, Guillaume Robert, Gilles Pagès, Arnaud Jacquel, Frédéric Luciano, Alexandre Puissant, Marcel Deckert, Rachid Benhida, Nina Fenouille and Sophie Raynaud and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Maeva Dufies

46 papers receiving 1.5k citations

Peers

Maeva Dufies

ONCOL

IMMUN

PRM

Shweta Joshi United States

Lisa Roberts United States

Jessica Adickes United States

Frédéric Stauffer Switzerland

Matthew R. Janes United States

Yoko Ueno Japan

Yukinori Minoshima Japan

Josef Brueggen Switzerland

Arianna Giacomini Italy

Mei Dong China

Shweta Joshi United States

Maeva Dufies

655 ×0.9

382 ×1.0

ONCOL

403 ×1.6

IMMUN

239 ×1.0

119 ×0.6

PRM

Citations per year, relative to Maeva Dufies Maeva Dufies (= 1×) peers Shweta Joshi

Countries citing papers authored by Maeva Dufies

Since Specialization

Citations

This map shows the geographic impact of Maeva Dufies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maeva Dufies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maeva Dufies more than expected).

Fields of papers citing papers by Maeva Dufies

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maeva Dufies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maeva Dufies. The network helps show where Maeva Dufies may publish in the future.

Co-authorship network of co-authors of Maeva Dufies

This figure shows the co-authorship network connecting the top 25 collaborators of Maeva Dufies. A scholar is included among the top collaborators of Maeva Dufies based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maeva Dufies. Maeva Dufies is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brest, Patrick, Marcel Deckert, Mickaël Ohanna, et al.. (2024). Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradation. Journal of Experimental & Clinical Cancer Research. 43(1). 335–335. 1 indexed citations

Montemagno, Christopher, Jérôme Durivault, Maeva Dufies, et al.. (2023). A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma. Molecular Oncology. 17(7). 1379–1401. 5 indexed citations

Bovio, Elena, Olivia Rastoin, Maeva Dufies, et al.. (2023). New Phenylspirodrimanes from the Sponge-Associated Fungus Stachybotrys chartarum MUT 3308. Marine Drugs. 21(3). 135–135. 8 indexed citations

Saâda-Bouzid, Esma, Damien Ambrosetti, Olivia Rastoin, et al.. (2022). Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma. Cell Reports Medicine. 3(9). 100659–100659. 23 indexed citations

Montemagno, Christopher, Benjamín Serrano, Jérôme Durivault, et al.. (2021). In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study. Biochemistry and Biophysics Reports. 27. 101098–101098. 2 indexed citations

Ambrosetti, Damien, Julien Boyer, Alexandre Bozec, et al.. (2021). The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy. Theranostics. 11(19). 9571–9586. 26 indexed citations

Contenti, Julie, Maeva Dufies, Julien Parola, et al.. (2020). Co‐culture of human fibroblasts, smooth muscle and endothelial cells promotes osteopontin induction in hypoxia. Journal of Cellular and Molecular Medicine. 24(5). 2931–2941. 7 indexed citations

Dufies, Maeva, Luc Demange, Sonia Martial, et al.. (2020). Synthesis and biological evaluation of 3-amino-1,2,4-triazole derivatives as potential anticancer compounds. Bioorganic Chemistry. 104. 104271–104271. 51 indexed citations

Torrino, Stéphanie, Maeva Dufies, Zied Djabari, et al.. (2019). PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness. Cancer Research. 79(13). 3268–3280. 29 indexed citations

10.

Giuliano, Sandy, Maeva Dufies, Papa Diogop Ndiaye, et al.. (2019). Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5. Theranostics. 9(4). 1181–1199. 24 indexed citations

11.

Dufies, Maeva, Cyril Ronco, Damien Ambrosetti, et al.. (2019). New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments. Theranostics. 9(18). 5332–5346. 36 indexed citations

12.

Ndiaye, Papa Diogop, Maeva Dufies, Sandy Giuliano, et al.. (2019). VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness. Theranostics. 9(3). 661–675. 26 indexed citations

13.

Dufies, Maeva, Adama Sidibé, A. Salomón, et al.. (2018). The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma. British Journal of Cancer. 118(9). 1179–1188. 24 indexed citations

14.

Martial, Sonia, Kévin Lebrigand, Nicolas Pons, et al.. (2017). Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma. Oncogenesis. 6(7). e354–e354. 48 indexed citations

15.

Marzag, Hamid, Guillaume Robert, Maeva Dufies, et al.. (2014). FeCl3-promoted and ultrasound-assisted synthesis of resveratrol O-derived glycoside analogs. Ultrasonics Sonochemistry. 22. 15–21. 18 indexed citations

16.

Robert, Guillaume, Alexandre Puissant, Maeva Dufies, et al.. (2012). The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production. Cell Death and Differentiation. 19(11). 1769–1778. 20 indexed citations

17.

Fenouille, Nina, Mélanie Tichet, Maeva Dufies, et al.. (2012). The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell Invasion. PLoS ONE. 7(7). e40378–e40378. 167 indexed citations

18.

Puissant, Alexandre, Maeva Dufies, Nina Fenouille, et al.. (2012). Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. Journal of Molecular Cell Biology. 4(4). 207–220. 32 indexed citations

19.

Fenouille, Nina, Alexandre Puissant, Maeva Dufies, et al.. (2010). Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC. Cancer Research. 70(23). 9659–9670. 52 indexed citations

20.

Grosso, Sébastien, Alexandre Puissant, Maeva Dufies, et al.. (2009). Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Molecular Cancer Therapeutics. 8(7). 1924–1933. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact